Hope Medicine has completed a Phase 2 trial of HMI-115, a monoclonal antibody that blocks the prolactin receptor for endometriosis treatment. The company announced results on October 7, 2025.
The randomized, double-blind, placebo-controlled study enrolled 108 women with surgically diagnosed endometriosis across the United States, Poland, and China over a 12-week treatment period. Patients in the 240 mg dose group experienced a 42% reduction in dysmenorrhea pain scores and a 52% reduction in non-menstrual pelvic pain scores compared to baseline. Both reductions were statistically significant.
The treatment did not cause typical perimenopausal symptoms and showed no significant changes in menstrual patterns, bone mineral density, or sex hormone levels including estradiol, LH, FSH, and progesterone. Most patients maintained normal menstrual periods. No treatment-related serious adverse events were reported.
Endometriosis affects approximately 190 million women worldwide and represents a market of approximately $180 billion. The condition occurs in about 10% of women of childbearing age and causes symptoms including pelvic pain, dysmenorrhea, painful intercourse, and infertility.
Hope Medicine is communicating with regulatory agencies including the FDA and China’s National Medical Products Administration to finalize the Phase 3 protocol. The company plans to initiate Phase 3 studies worldwide.
Hope Medicine is a clinical-stage biopharmaceutical company based in Beijing, Shanghai, and Nanjing, China. The company was founded based on research from Professor Rui-Ping Xiao’s laboratory at the Institute of Molecular Medicine of Peking University.
